EMA's CHMP adopts positive opinion for Pharmaxis' cystic fibrosis drug
This article was originally published in Scrip
Executive Summary
Re-examination requests submitted by two companies to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) have resulted in mixed fates with Australian company, Pharmaxis coming out better than the Netherlands' Amsterdam Molecular Therapeutics.